Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

Company Overview

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments. The company also provides solutions for flow cytometry, microbiology, biosurgery, vascular care, urology and oncology, along with technologies designed to improve healthcare worker and patient safety.

Founded in 1897, BD has expanded from a medical supply business into a diversified medical technology company serving customers in the United States and international markets. Its operations are organized around medical products and solutions, life sciences and interventional businesses, with products distributed through healthcare systems, laboratories and other channels worldwide.

BD is headquartered in Franklin Lakes, New Jersey. Tom Polen serves as the company’s chairman, president and chief executive officer.

Key Stats

• Today's Range: $197.15 to $200.42
• 50-Day Range: $176.18 to $200.21
• 52-Week Range: $127.59 to $200.47
• Volume: 1.30 million shs
• Average Volume: 2.44 million shs
• Market Capitalization: $54.82 billion
• P/E Ratio: 59.93
• Dividend Yield: 2.11%
• Price Target: $185.07
• Consensus Rating: Moderate Buy

Becton, Dickinson and Company Stock Analysis - MarketRank™

Becton, Dickinson and Company scored higher than 75% of companies evaluated by MarketBeat, and ranked 119th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Becton, Dickinson and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 8 buy ratings, 8 hold ratings, and 1 sell rating.

Downside Risk

Becton, Dickinson and Company has a consensus price target of $185.07, representing about 7.0% downside from its current price of $198.96.

Amount of Analyst Coverage

Becton, Dickinson and Company has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 4.50%

Earnings Growth

Earnings for Becton, Dickinson and Company are expected to grow by 4.50% in the coming year, from $12.67 to $13.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Becton, Dickinson and Company is 59.93, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.76.

Price to Earnings Ratio vs. Sector

The P/E ratio of Becton, Dickinson and Company is 59.93, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.67.

Price to Earnings Growth Ratio

Becton, Dickinson and Company has a PEG Ratio of 13.10. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Becton, Dickinson and Company has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.56% of the float of Becton, Dickinson and Company has been sold short.

Short Interest Ratio / Days to Cover

Becton, Dickinson and Company has a short interest ratio ("days to cover") of 4.88.

Change versus previous month

Short interest in Becton, Dickinson and Company has recently decreased by 13.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Becton, Dickinson and Company pays a meaningful dividend of 2.16%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Becton, Dickinson and Company has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of Becton, Dickinson and Company is 126.51%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Becton, Dickinson and Company will have a dividend payout ratio of 31.72% next year. This indicates that Becton, Dickinson and Company will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.10

News Sentiment

Becton, Dickinson and Company has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 27 news articles for Becton, Dickinson and Company this week, compared to 8 articles on an average week.

Search Interest

Only 14 people have searched for BDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

7 people have added Becton, Dickinson and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Becton, Dickinson and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,265,855.00 in company stock.

Percentage Held by Insiders

0.40% of the stock of Becton, Dickinson and Company is held by insiders.

Percentage Held by Institutions

86.97% of the stock of Becton, Dickinson and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Record date for 9/30 Dividend: 9/09/2026
• Ex-Dividend for 9/30 Dividend: 9/09/2026
• Dividend Payable: 9/30/2026
• Today: 10/23/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:BDX
• CIK: 10795
• Web: www.bd.com
• Phone: (201) 847-6800
• Fax: 201-847-6475
• Employees: 72,000
• Year Founded: 1897

Price Target and Rating

• Average Price Target for Becton, Dickinson and Company: $185.07
• High Price Target: $210.00
• Low Price Target: $150.00
• Potential Upside/Downside: -7.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.32
• Trailing P/E Ratio: 59.93
• Forward P/E Ratio: 15.70
• P/E Growth: 13.1
• Net Income: $1.68 billion
• Net Margins: 4.52%
• Pretax Margin: 8.59%
• Return on Equity: 14.79%
• Return on Assets: 6.93%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 0.87
• Quick Ratio: 0.51

Sales & Book Value

• Annual Sales: $21.84 billion
• Price / Sales: 2.51
• Cash Flow: $23.63 per share
• Price / Cash Flow: 8.42
• Book Value: $88.58 per share
• Price / Book: 2.25

Miscellaneous

• Outstanding Shares: 275,540,000
• Free Float: 274,438,000
• Market Cap: $54.82 billion
• Optionable: Optionable
• Beta: 0.21